Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by EternalPonzion Feb 13, 2020 8:15pm
204 Views
Post# 30688738

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FYI - George W. Haywood - SCHEDULE 13G - February 13, 2020

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FYI - George W. Haywood - SCHEDULE 13G - February 13, 2020You don't dispose that much of your position on a whim. There was a reason, and yes he locked in gains but there was no credible reason to think Phase 3 would not be successful. You don't leave a good chance at an additional double from what you've already gained on the table unless you know there is a potential to make a triple-double by buying back later knowing there is a very likely probability the stock will be punished. I've seen so many regret postings where shareholders wished they had sold. You didn't sell because you didn't believe the T1 trial would be deemed a failure. No one could have foreseen that the placebo group results would be so unusual. There is no doubt that certain people were tipped off because there was no logical reason to sell before T1 were released. Cheating definitely occurred. Just needs to be proven. I'm certain they tried to cover their tracks well so it won't be easy.
Bullboard Posts